Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CVS Health 1Q Profit, Sales Rise As U.S. Ramps Up Covid-19 Vaccinations

05/04/2021 | 07:02am EDT

By Dave Sebastian

CVS Health Corp. said its profit and sales rose for the latest quarter, booking gains from inoculations as the U.S. stepped up its rollout of Covid-19 vaccines.

The pharmacy and insurance giant on Tuesday posted net income attributable to the company of $2.22 billion for the first quarter, compared with $2 billion in the same period last year. Earnings were $1.68 a share, compared with $1.53 a share in the year-ago period.

Adjusted earnings were $2.04 a share, ahead of Wall Street estimates.

CVS, rival Walgreens Boots Alliance Inc., as well as supermarket chain Kroger Co. and Walmart Inc. have been pushing to get consumers to visit their locations to receive vaccines. More than 40% of all U.S. adults have been fully vaccinated, according to the Centers for Disease Control and Prevention data, and the daily number of new Covid-19 cases has been declining. Governors across the U.S. are now broadly rolling back restrictions implemented during the pandemic.

Revenue rose 3.5% to $69.1 billion, just above the FactSet consensus of $68.36 billion.

Same-store sales, or those at retail pharmacy stores that had been operating for more than one year, rose 0.4%.

Revenue in the company's segment that fulfills medication prescriptions and sells general products rose 2.3% to $23.27 billion, driven by higher Covid-19 testing and vaccinations.

Revenue in the pharmacy-services segment, which provides pharmacy-benefit management services to employers, health plans, government employee groups and government-sponsored programs, rose 3.8%, partly driven by new business.

Revenue in the healthcare benefits segment, which offers insured and self-insured medical, pharmacy, dental and behavioral health products and services, rose 6.7%, driven by growth in the government services business, the company said. Medical membership as of March 31 was 23.6 million, up 214,000 members from Dec. 31, it said.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

05-04-21 0702ET

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH CORPORATION 0.07% 84.33 Delayed Quote.23.47%
DJ INDUSTRIAL 1.06% 34382.13 Delayed Quote.9.74%
THE KROGER CO. 1.06% 37.2 Delayed Quote.17.13%
WALGREENS BOOTS ALLIANCE, INC. 1.05% 54.71 Delayed Quote.35.76%
WALMART INC. 0.93% 139.52 Delayed Quote.-3.21%
05:32pINSIDER TRENDS : CVS Health Insider Gets Stock Award, Prolongs Buy Trend
05:27pINSIDER TRENDS : CVS Health Insider Receives Stock Award, Trend of Buys Extended
05:25pINSIDER TRENDS : CVS Health Insider Receives Stock Award, Buy Trend Intact
05:24pINSIDER TRENDS : CVS Health Insider Gets Stock Award, Extends Buy Trend
05:21pINSIDER TRENDS : CVS Health Insider Granted Stock Award, Extends Buy Trend
05/13CVS Health, Walgreens, Rite Aid Offering Pfizer COVID-19 Vaccine to Adolescen..
05/12CVS HEALTHá : COVID-19 Vaccine Appointments Now Available for Adolescents Ages 1..
05/12CVS HEALTHá : Mizuho Securities Adjusts CVS Health's Price Target to $98 From $8..
05/11CVS PHARMACYá : Upgrades Prescription Delivery Benefit for CarePass Members
05/10INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of CVS Hea..
More news
Financials (USD)
Sales 2021 282 B - -
Net income 2021 8 230 M - -
Net Debt 2021 50 189 M - -
P/E ratio 2021 13,6x
Yield 2021 2,37%
Capitalization 111 B 111 B -
EV / Sales 2021 0,57x
EV / Sales 2022 0,53x
Nbr of Employees 256 500
Free-Float 75,6%
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 93,60 $
Last Close Price 84,33 $
Spread / Highest target 26,9%
Spread / Average Target 11,0%
Spread / Lowest Target -3,95%
EPS Revisions
Managers and Directors
Karen S. Lynch President, Chief Executive Officer & Director
Eva C. Boratto Chief Financial Officer & Executive Vice President
David Wyatt Dorman Chairman
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Sector and Competitors